InflaRx N.V. logo
InflaRx N.V. IFRX
$ 0.92 3.97%

Annual report 2024
added 02-21-2026

report update icon

InflaRx N.V. Balance Sheet 2011-2026 | IFRX

Annual Balance Sheet InflaRx N.V.

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- - -32.3 M -22.5 M -123 M -29.1 M -3.3 M - - - -

Long Term Debt

- - - - - 331 K - - - - - - - -

Long Term Debt Current

406 K 374 K 369 K 366 K 339 K 515 K - - - - - - - -

Total Non Current Liabilities

- - - - 254 K 370 K 67 K 17 K 53.5 M 20.8 M - - - -

Total Liabilities

14.6 M 17.6 M 14.1 M 19.9 M 10.4 M 14.4 M 7.82 M 4.78 M 55.2 M 21.2 M - - - -

Deferred Revenue

- - - - - - - 15 K - - - - - -

Retained Earnings

- - - - -168 M -109 M -62.8 M 117 M -27.1 M -18.1 M - - - -

Total Assets

76 M 120 M 102 M 125 M 88.2 M 122 M 159 M 124 M 29.5 M 3.59 M - - - -

Cash and Cash Equivalents

18.4 M 12.8 M 16.3 M 26.2 M 26 M 33.1 M 55.4 M 123 M 29.1 M 3.3 M - - - -

Book Value

61.4 M 103 M 88.3 M 105 M 77.9 M 107 M 151 M 119 M -25.7 M -17.6 M - - - -

Total Shareholders Equity

- - - - 77.9 M 107 M 151 M 119 M -25.7 M -17.6 M - - - -

All numbers in EUR currency

Quarterly Balance Sheet InflaRx N.V.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - - 1.07 M - - - 221 K - - - 331 K - 647 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - 1.1 M - - - 254 K - - - 370 K - 698 K - 67.9 K - - - 17 K - - - 53.5 M - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - - - 19.9 M - - - 10.4 M - - - 14.4 M - 14.1 M - 7.82 M - - - 4.78 M - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - - - -214 M - - - -168 M - - - -134 M - -106 M - -81.1 M - - - -51.3 M - - - -27.1 M - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - - - 125 M - - - 88.2 M - - - 122 M - 145 M - 159 M - - - 124 M - - - 29.5 M - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - - - 26.2 M - - - 26 M - - - 33.1 M - 54.1 M - 55.4 M - 156 M - 123 M - - - 29.1 M - - - 3.3 M - - - 6.62 M - - - - - - - - - - - - - - -

Book Value

- - - - 105 M - - - 77.9 M - - - 107 M - 131 M - 151 M - - - 119 M - - - 29.5 M - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - - - 105 M - - - 77.9 M - - - 107 M - 131 M - 151 M - 162 M - 119 M - - - -25.7 M - - - -17.6 M - - - -12.9 M - - - - - - - - - - - - - - -

All numbers in EUR currency

Balance Sheet is a fundamental financial report of InflaRx N.V., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.81 0.15 % $ 4.42 M chinaChina
argenx SE argenx SE
ARGX
$ 836.39 -0.46 % $ 25 B niderlandNiderland
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 234.52 -0.2 % $ 5 B danmarkDanmark
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.44 3.42 % $ 8.28 B australiaAustralia
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
BioVie BioVie
BIVI
$ 1.24 -0.8 % $ 1.83 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 61.58 -1.66 % $ 11.7 B usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 4.56 -1.94 % $ 384 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Capricor Therapeutics Capricor Therapeutics
CAPR
$ 28.24 1.18 % $ 756 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 165.14 -2.83 % $ 8.22 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
$ 0.31 -61.59 % $ 42.2 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 12.21 -3.48 % $ 804 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Biogen Biogen
BIIB
$ 191.78 -1.72 % $ 28.1 B usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Baudax Bio Baudax Bio
BXRX
- 0.59 % $ 63 K usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 110.5 -0.35 % $ 27.2 B germanyGermany
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 14.64 -0.17 % $ 4.52 B usaUSA